schliessen

Filtern

 

Bibliotheken

Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.biomaterials.2015.07.027 Byline: Peng Zhang, Jiang Li, Mohammed Ghazwani, Wenchen Zhao, Yixian Huang, Xiaolan Zhang, Raman Venkataramanan, Song Li Abstract: A simple PEGylated peptidic nanocarrier, PEG.sub.500... Full description

Journal Title: Biomaterials 2015, Vol.67, p.104(11)
Main Author: Zhang, Peng
Other Authors: Li, Jiang , Ghazwani, Mohammed , Zhao, Wenchen , Huang, Yixian , Zhang, Xiaolan , Venkataramanan, Raman , Li, Song
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Cengage Learning, Inc.
ID: ISSN: 0142-9612
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa431648023
title: Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy
format: Article
creator:
  • Zhang, Peng
  • Li, Jiang
  • Ghazwani, Mohammed
  • Zhao, Wenchen
  • Huang, Yixian
  • Zhang, Xiaolan
  • Venkataramanan, Raman
  • Li, Song
subjects:
  • Cancer – Analysis
  • Colon Cancer – Analysis
  • Cancer Prevention – Analysis
  • Pharmacogenomics – Analysis
  • Fluorescence – Analysis
  • Anthracyclines – Analysis
  • Chemotherapy – Analysis
ispartof: Biomaterials, 2015, Vol.67, p.104(11)
description: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.biomaterials.2015.07.027 Byline: Peng Zhang, Jiang Li, Mohammed Ghazwani, Wenchen Zhao, Yixian Huang, Xiaolan Zhang, Raman Venkataramanan, Song Li Abstract: A simple PEGylated peptidic nanocarrier, PEG.sub.5000-lysyl-([alpha]-Fmoc-[epsilon]-Cbz-lysine).sub.2 (PLFCL), was developed for effective co-delivery of doxorubicin (DOX) and dasatinib (DAS) for combination chemotherapy. Significant synergy of DOX and DAS in inhibition of cancer cell proliferation was demonstrated in various types of cancer cells, including breast, prostate, and colon cancers. Co-encapsulation of the two agents was facilitated by incorporation of 9-Fluorenylmethoxycarbonyl (Fmoc) and carboxybenzyl (Cbz) groups into a nanocarrier for effective carrier-drug interactions. Spherical nanomicelles with a small size of [approximately equal to]30 nm were self-assembled by PLFCL. Strong carrier/drug intermolecular [pi]-[pi] stacking was demonstrated in fluorescence quenching and UV absorption. Fluorescence study showed more effective accumulation of DOX in nuclei of cancer cells following treatment with DOX&DAS/PLFCL in comparison with cells treated with DOX/PLFCL. DOX&DAS/PLFCL micelles were also more effective than other treatments in inhibiting the proliferation and migration of cultured cancer cells. Finally, a superior anti-tumor activity was demonstrated with DOX&DAS/PLFCL. A tumor growth inhibition rate of 95% was achieved at a respective dose of 5 mg/kg for DOX and DAS in a murine breast cancer model. Our nanocarrier may represent a simple and effective system that could facilitate clinical translation of this promising multi-agent regimen in combination chemotherapy. Author Affiliation: (a) Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA (b) Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA (c) University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA Article History: Received 30 June 2015; Revised 11 July 2015; Accepted 13 July 2015
language: eng
source: Cengage Learning, Inc.
identifier: ISSN: 0142-9612
fulltext: fulltext
issn:
  • 0142-9612
  • 01429612
url: Link


@attributes
ID151668262
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid431648023
sourceidgale_ofa
recordidTN_gale_ofa431648023
sourceformatXML
sourcesystemPC
galeid431648023
display
typearticle
titleEffective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy
creatorZhang, Peng ; Li, Jiang ; Ghazwani, Mohammed ; Zhao, Wenchen ; Huang, Yixian ; Zhang, Xiaolan ; Venkataramanan, Raman ; Li, Song
ispartofBiomaterials, 2015, Vol.67, p.104(11)
identifierISSN: 0142-9612
subjectCancer – Analysis ; Colon Cancer – Analysis ; Cancer Prevention – Analysis ; Pharmacogenomics – Analysis ; Fluorescence – Analysis ; Anthracyclines – Analysis ; Chemotherapy – Analysis
descriptionTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.biomaterials.2015.07.027 Byline: Peng Zhang, Jiang Li, Mohammed Ghazwani, Wenchen Zhao, Yixian Huang, Xiaolan Zhang, Raman Venkataramanan, Song Li Abstract: A simple PEGylated peptidic nanocarrier, PEG.sub.5000-lysyl-([alpha]-Fmoc-[epsilon]-Cbz-lysine).sub.2 (PLFCL), was developed for effective co-delivery of doxorubicin (DOX) and dasatinib (DAS) for combination chemotherapy. Significant synergy of DOX and DAS in inhibition of cancer cell proliferation was demonstrated in various types of cancer cells, including breast, prostate, and colon cancers. Co-encapsulation of the two agents was facilitated by incorporation of 9-Fluorenylmethoxycarbonyl (Fmoc) and carboxybenzyl (Cbz) groups into a nanocarrier for effective carrier-drug interactions. Spherical nanomicelles with a small size of [approximately equal to]30 nm were self-assembled by PLFCL. Strong carrier/drug intermolecular [pi]-[pi] stacking was demonstrated in fluorescence quenching and UV absorption. Fluorescence study showed more effective accumulation of DOX in nuclei of cancer cells following treatment with DOX&DAS/PLFCL in comparison with cells treated with DOX/PLFCL. DOX&DAS/PLFCL micelles were also more effective than other treatments in inhibiting the proliferation and migration of cultured cancer cells. Finally, a superior anti-tumor activity was demonstrated with DOX&DAS/PLFCL. A tumor growth inhibition rate of 95% was achieved at a respective dose of 5 mg/kg for DOX and DAS in a murine breast cancer model. Our nanocarrier may represent a simple and effective system that could facilitate clinical translation of this promising multi-agent regimen in combination chemotherapy. Author Affiliation: (a) Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA (b) Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA (c) University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA Article History: Received 30 June 2015; Revised 11 July 2015; Accepted 13 July 2015
languageeng
sourceCengage Learning, Inc.
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1OneFile
creatorcontrib
0Zhang, Peng
1Peng Zhang
2Li, Jiang
3Ghazwani, Mohammed
4Zhao, Wenchen
5Huang, Yixian
6Zhang, Xiaolan
7Venkataramanan, Raman
8Li, Song
titleEffective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
descriptionTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.biomaterials.2015.07.027 Byline: Peng Zhang, Jiang Li, Mohammed Ghazwani, Wenchen Zhao, Yixian Huang, Xiaolan Zhang, Raman Venkataramanan, Song Li Abstract: A simple PEGylated peptidic nanocarrier, PEG.sub.5000-lysyl-([alpha]-Fmoc-[epsilon]-Cbz-lysine).sub.2 (PLFCL), was developed for effective co-delivery of doxorubicin (DOX) and dasatinib (DAS) for combination chemotherapy. Significant synergy of DOX and DAS in inhibition of cancer cell proliferation was demonstrated in various types of cancer cells, including breast, prostate, and colon cancers. Co-encapsulation of the two agents was facilitated by incorporation of 9-Fluorenylmethoxycarbonyl (Fmoc) and carboxybenzyl (Cbz) groups into a nanocarrier for effective carrier-drug interactions. Spherical nanomicelles with a small size of [approximately equal to]30 nm were self-assembled by PLFCL. Strong carrier/drug intermolecular [pi]-[pi] stacking was demonstrated in fluorescence quenching and UV absorption. Fluorescence study showed more effective accumulation of DOX in nuclei of cancer cells following treatment with DOX&DAS/PLFCL in comparison with cells treated with DOX/PLFCL. DOX&DAS/PLFCL micelles were also more effective than other treatments in inhibiting the proliferation and migration of cultured cancer cells. Finally, a superior anti-tumor activity was demonstrated with DOX&DAS/PLFCL. A tumor growth inhibition rate of 95% was achieved at a respective dose of 5 mg/kg for DOX and DAS in a murine breast cancer model. Our nanocarrier may represent a simple and effective system that could facilitate clinical translation of this promising multi-agent regimen in combination chemotherapy. Author Affiliation: (a) Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA (b) Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA (c) University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA Article History: Received 30 June 2015; Revised 11 July 2015; Accepted 13 July 2015
subject
0Cancer–Analysis
1Colon cancer–Analysis
2Cancer prevention–Analysis
3Pharmacogenomics–Analysis
4Fluorescence–Analysis
5Anthracyclines–Analysis
6Chemotherapy–Analysis
general
0English
1Elsevier B.V.
2Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa431648023
issn
00142-9612
101429612
rsrctypearticle
creationdate2015
startdate20151001
enddate20151001
recordtypearticle
addtitleBiomaterials
searchscopeOneFile
citationpf 104 vol 67
sort
titleEffective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
authorZhang, Peng ; Li, Jiang ; Ghazwani, Mohammed ; Zhao, Wenchen ; Huang, Yixian ; Zhang, Xiaolan ; Venkataramanan, Raman ; Li, Song
creationdate20151001
lso0120151001
facets
frbrgroupid-8709186436248345749
frbrtype6
languageeng
creationdate2015
topic
0Cancer–Analysis
1Colon Cancer–Analysis
2Cancer Prevention–Analysis
3Pharmacogenomics–Analysis
4Fluorescence–Analysis
5Anthracyclines–Analysis
6Chemotherapy–Analysis
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Zhang, Peng
1Li, Jiang
2Ghazwani, Mohammed
3Zhao, Wenchen
4Huang, Yixian
5Zhang, Xiaolan
6Venkataramanan, Raman
7Li, Song
jtitleBiomaterials
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Zhang
1Li
2Ghazwani
3Zhao
4Huang
5Venkataramanan
aufirst
0Peng
1Jiang
2Mohammed
3Wenchen
4Yixian
5Xiaolan
6Raman
7Song
au
0Zhang, Peng
1Li, Jiang
2Ghazwani, Mohammed
3Zhao, Wenchen
4Huang, Yixian
5Zhang, Xiaolan
6Venkataramanan, Raman
7Li, Song
atitleEffective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy
jtitleBiomaterials
risdate20151001
volume67
spage104
issn0142-9612
formatjournal
genrearticle
ristypeJOUR
abstractTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.biomaterials.2015.07.027 Byline: Peng Zhang, Jiang Li, Mohammed Ghazwani, Wenchen Zhao, Yixian Huang, Xiaolan Zhang, Raman Venkataramanan, Song Li Abstract: A simple PEGylated peptidic nanocarrier, PEG.sub.5000-lysyl-([alpha]-Fmoc-[epsilon]-Cbz-lysine).sub.2 (PLFCL), was developed for effective co-delivery of doxorubicin (DOX) and dasatinib (DAS) for combination chemotherapy. Significant synergy of DOX and DAS in inhibition of cancer cell proliferation was demonstrated in various types of cancer cells, including breast, prostate, and colon cancers. Co-encapsulation of the two agents was facilitated by incorporation of 9-Fluorenylmethoxycarbonyl (Fmoc) and carboxybenzyl (Cbz) groups into a nanocarrier for effective carrier-drug interactions. Spherical nanomicelles with a small size of [approximately equal to]30 nm were self-assembled by PLFCL. Strong carrier/drug intermolecular [pi]-[pi] stacking was demonstrated in fluorescence quenching and UV absorption. Fluorescence study showed more effective accumulation of DOX in nuclei of cancer cells following treatment with DOX&DAS/PLFCL in comparison with cells treated with DOX/PLFCL. DOX&DAS/PLFCL micelles were also more effective than other treatments in inhibiting the proliferation and migration of cultured cancer cells. Finally, a superior anti-tumor activity was demonstrated with DOX&DAS/PLFCL. A tumor growth inhibition rate of 95% was achieved at a respective dose of 5 mg/kg for DOX and DAS in a murine breast cancer model. Our nanocarrier may represent a simple and effective system that could facilitate clinical translation of this promising multi-agent regimen in combination chemotherapy. Author Affiliation: (a) Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA (b) Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA (c) University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA Article History: Received 30 June 2015; Revised 11 July 2015; Accepted 13 July 2015
pubElsevier B.V.
lad01gale_ofa
date2015-10-01